Concord Biotech Acquires 75% Stake in US-Based Stellon Biotech

MT Newswires Live
2025/07/02

Concord Biotech (NSE:CONCORDBIO, BOM:543960) has acquired a 75% in US-based Stellon Biotech for $15,000, making it a subsidiary, to expand its business operations in the US, according to a Wednesday filing to the Indian stock exchanges.

The company subscribed 15 million equity shares of Stellon Biotech at $0.0001 per share.

Stellon is currently in its pre-revenue phase and was formed to support the marketing and commercialization of products developed by Concord Biotech.

The equity shares against the current investment will be allotted within 90 days.

The company's shares were down over 1% in recent trade.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10